– Find new drug candidates through conducting joint research for 2 years
– The goal of developing therapies to reduce the treatment burden for patients

MEDIPOST announced on Jun 7, that it has signed a joint research agreement with LG Chemical to develop a new form of treatment.

The two companies plan to work together for two years to develop new drug candidates for stem cell therapies derived from the umbilical cord blood.

MEDIPOST is responsible for the development and provision of the umbilical cord blood-derived mesenchymal stem cells and the establishment of the characteristics analysis items, and LG Chemical is responsible for seeking and researching a development strategy on new drug candidates including the selection of target genes and the generation of mesenchymal stem cells using genetic engineering techniques.

MEDIPOST’s current flagship product, CARTISTEM^®, is an allogeneic hematopoietic-derived mesenchymal stem cell therapy that is effective in regenerating knee cartilage defects in patients with degenerative arthritis. In addition, the 5-year long-term follow-up clinical trials have been recognized for their effectiveness and safety, while the number of surgical hospitals and patients has been recorded to be steadily increasing.

A MEDIPOST representative said, “with this joint research, we have been able to utilize LG Chemical’s excellent gene discovery and injection ability and development strategy in the development of therapeutics,” and said that “the goal is to develop a therapeutic that aims to perform the underlying treatment of the disease and dramatically reduces the patient’s treatment burden.”